Global Infectious Disease Diagnostics Market Insights, Size and Growth Forecast To 2027
The global infectious disease diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to reach 41.6 billion by 2027. The growth is primarily attributed to prevalence of infectious diseases, global outbreak of COVID-19, technological advancements, and increased demands for decentralized diagnostic POC kits. However, unfavorable and inadequate reimbursement scenarios can impact the growth of the market.
By Product: Reagents, kits and Consumables dominated the infectious disease diagnostics market in 2020
Reagents, kits and consumables segment accounted for the largest share of infectious disease diagnostics market. The largest share of this segment is mainly attributed to frequent purchase of these products due to their recurrent usage.
POC testing segment to account for fastest growth
By type of testing, infectious disease diagnostics market is segmented into laboratory testing and POC testing. During the forecast period, POC testing accounted for fastest growth. Highest CAGR can be attributed to faster diagnosis and need to closely monitor patients.
By Technology: Immunodiagnostics segment accounted for largest share
On the basis of technology, infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays and other technologies. Immunodiagnostics segment accounted for largest share in 2020. The growth of this segment was mainly attributed to increasing demand for immunoassays in COVID-19 testing, POC infectious disease testing, rising trend for automation and development of immunodiagnostic tests.
“The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).”
Access Full Report? Inquire Here@
https://www.sperresearch.com/report-store/Infectious-Disease-Diagnostics.aspx?sample=1
https://www.sperresearch.com/report-store/Infectious-Disease-Diagnostics.aspx?sample=1
By Disease: Hepatitis to hold the largest share of Infectious disease diagnostics market
By disease type, hepatitis segment held the largest share of infectious disease diagnostics market in 2020. The growth is mainly driven by increasing blood transfusions and donations, prevalence of hepatitis B & C infections, rising geriatric population and benefits offered by POC instruments and kits.
Diagnostic laboratory: Accounted for largest share of Infectious disease diagnostics market
By end user, diagnostic laboratory segment accounted for highest CAGR. This can be attributed to strengthening of healthcare infrastructure and prevalence of infectious disease.
By Region: Asia Pacific fastest growing market
In 2020, North America accounted for the largest share of infectious disease diagnostics. The largest share is mainly attributed to highly developed healthcare system in US and Canada, availability of leading national clinical laboratories and technologically advanced instruments. However, Asia Pacific region is expected to grow at fastest CAGR during the forecast period. The growth is driven by rapid urbanization, government initiatives, increased investments on healthcare system and improved accessibility to diagnostic services.
Competitive Scenario
- Abbott Laboratories (US)
- F. Hoffmann-La Roche Ltd(Switzerland)
- bioMérieux SA (France)
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Quidel Corporation (US)
- Hologic, Inc. (US)
- Siemens Healthineers AG (Germany)
- Becton, Dickinson and Company (US)
- PerkinElmer Inc. (US)
- QIAGEN (Netherlands)
- Grifols S.A. (Spain)
- DiaSorin S.p.A (Italy)
- Bio-Rad Laboratories Inc. (US)
- Sysmex Corporation (Japan)
- Ortho Clinical Diagnostics (US)
- Luminex Corporation (US)
- Meridian Bioscience (US)
- Genetic Signatures (Australia)
- OraSure Technologies (US)
- Trinity Biotech Plc. (Ireland)
- Chembio Diagnostic Systems
- Inc. (US)
- Seegene Inc. (South Korea)
- Co-Diagnostics Inc. (US)
- ELITechGroup (France)
- Epitope Diagnostics, Inc. (US)
- Trivitron Healthcare (India)
- Meril Life Sciences Pvt. Ltd. (India)
- InBios International Inc. (US)
- and ABACUS Diagnostica Oy (Finland)
Comments
Post a Comment